Research Article
The Application of Fluorescence Optical Imaging in Systemic Sclerosis
Table 1
Characterization of the study cohort.
| | | Total study cohort | Iloprost group | Alprostadil group |
| | Patients | | | | | Women | | | | | Men | | | | | Mean age and standard deviation in years | 63.7 ± 8.7 | 64.4 ± 7.6 | 61.4 ± 12.4 | | Disease duration and standard deviation in years | 12.1 ± 10.0 | 10.4 ± 8.0 | 17.6 ± 14.4 | | Laboratory findings | | | | | C-reactive protein (mean and standard deviation) | 3.2 ± 1.8 mg/L | 3.3 ± 2.1 mg/L | 2.9 ± 1.3 mg/L | | Immunological findings | | | | | Antinuclear Antibodies (ANA) positive | (33.3%) | (31.3%) | (40.0%) | | Antitopoisomerase I (anti-SCL70) positive | (4.8%) | (6.3%) | (0%) | | ANA and anti-SCL70 positive | (33.3%) | (37.5%) | (20.0%) | | Anticentromere Antibodies (ACA) positive | (14.3%) | (12.5%) | (20.0%) | | Comedication | | | | | Calcium channel blockers | (42.8%) | (37.5%) | (60.0%) | | Immunosuppressive agents | | | | | Mycophenolate-mofetil | (19.0%) | (25.0%) | (0%) | | Azathioprine | (42.8%) | (43.8%) | (43.8%) | | Leflunomide | (4.8%) | (6.3%) | (0%) |
|
|
